Antidepressant use in pregnancy: New concerns, old dilemmas

Expert Review of Neurotherapeutics

Volumn 7, Issue 7, 2007, Pages 761-764

  Chambers, Christina ^a,b   Moses Kolko, Eydie ^c   Wisner, Katherine L ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCSD MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; PAROXETINE; PLACEBO; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR;

BIRTH DEFECT; CLEFT PALATE; CONGENITAL HEART MALFORMATION; DRUG WITHDRAWAL; EDITORIAL; FETUS DEVELOPMENT; FIRST TRIMESTER PREGNANCY; HUMAN; LIFESPAN; MAJOR DEPRESSION; MOOD DISORDER; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEURAL TUBE DEFECT; PREGNANT WOMAN; RISK FACTOR; TERATOGENESIS;

ANTIDEPRESSIVE AGENTS; DEPRESSION; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY TRIMESTER, FIRST; PRENATAL EXPOSURE DELAYED EFFECTS;

EID: 34447125669     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.7.7.761     Document Type: Editorial

References (30)

1. Kessler RC, Berglund P, Demler O et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289, 3095-3105 (2003).
2. Blazer DG, Kessler RC, McGonagle KA, Swartz MS. The prevalence and distribution of major depression in a national community sample: The National Comorbidity Survey. Am. J. Psychiatry 151, 979-986 (1994).
3. Kendell RE, Chalmers JC, Platz C. Epidemiology of puerperal psychoses. Br. J. Psychiatry 150, 662-673 (1987).
4. Munk-Olsen T, Laursen TM, Pedersen CB, Mors O, Mortensen PB. New parents and mental disorders: a population-based register study. JAMA 296, 2582-2589 (2006).
5. Mitchell AA. Systematic identification of drugs that cause birth defects - a new opportunity. N. Engl. J. Med. 349, 2556-2559 (2003).
6. Lo WY, Friedman JM. Teratogenicity of recently introduced medications in human pregnancy. Obstet. Gynecol. 100, 465-473 (2002).
7. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N. Engl. J. Med. 335, 1010-1015 (1996).
8. Kulin NA, Pastuszak A, Sage SR et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA 279, 609-610 (1998).
9. Källén BA, Otterblad Olausson P. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res. Part A Clin. Mol. Teratol. 79(4), 301-308 (2007).
10. Berard A, Ramos E, Rey E, Blais L, St-Andre M, Oraichi D. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res. B Dev. Reprod. Toxicol. 80(1), 18-27 (2007).
11. Wogelius P, Norgaard M, Gislum M et al. Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology 17, 701-704 (2006).
12. Malm H, Klaukka T, Neuvonen PJ. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet. Gynecol. 106, 1289-1296 (2005).
13. Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch. Gen. Psychiatry 63, 898-906 (2006).
14. Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure. Am. J. Psychiatry 159, 2055-2061 (2002).
15. Moses-Kolko EL, Bogen D, Perel J et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors. JAMA 293, 2372-2383 (2005).
16. Chambers CD, Hernandez-Diaz S, Van Marter LJ et al. Selective serotoninreuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N. Engl. J. Med. 354, 579-587 (2006).
17. Nulman I, Rovet J, Stewart D et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N. Engl. J. Med. 336, 258-262 (1997).
18. Nulman I, Rovet J, Stewart DE et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am. J. Psychiatry 159, 1889-1895 (2002).
19. Misri S, Reebye P, Kendrick K et al. Internalizing behaviors in 4-year-old children exposed in utero to psychotropic medications. Am. J. Psychiatry 163, 1026-1032 (2006).
20. Murray L. The impact of postnatal depression on infant development. J. Child Psychol. Psychiatry 33, 543-561 (1992).
21. Casper RC, Fleisher BE, Lee-Ancajas JC et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drug during pregnancy. J. Pediatr. 142, 402-408 (2003).
22. Oberlander TF, Grunau RE, Fitzgerald C, Papsdorf M, Rurak D, Riggs W. Pain reactivity in 2-month-old infants after prenatal and postnatal serotonin reuptake inhibitor medication exposure. Pediatrics 115, 411-425 (2005).
23. Bonari L, Pinto N, Ahn C, Einarson A, Steiner M, Koren G. Perinatal risks of untreated depression during pregnancy. Can. J. Psychiatry 49, 726-735 (2004).
24. Cohen LS, Altshuler LL, Harlow BL et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 295, 499-507 (2006).
25. Bonari L, Koren G, Einarson TR, Jasper JD, Taddio A, Einarson A. Use of antidepressants by pregnant women: evaluation of perception of risk, efficacy of evidence based counseling and determinants of decision making. Arch. Womens Ment. Health 8, 214-220 (2005).
26. Honein MA, Moore CA, Lyon Daniel K, Erickson JD. Problems with informing women adequately about teratogen risk: some barriers to preventing exposures to known teratogens. Teratology 65(5), 202-204 (2002).
27. Wisner K, Zarin D, Holmboe E et al. Risk-benefit decision making for treatment of depression during pregnancy. Am. J. Psychiatry 157, 1933-1940 (2000).
28. GlaxoSmithKline Clinical Trials Database - paroxetine http://ctr.gsk.co.uk/Summary/paroxetine/studylist.asp
29. Organization of Teratology Information Specialists http://otispregnancy. org
30. US FDA Office of Women's Health pregnancy registry www.fda.gov/womens/ registries/default.htm